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Introduction
Micro RNAs (miRNAs) are naturally occurring, noncoding 
small RNAs, which regulate the expression of target genes1 
by degradation of their mRNA and/or block of their transla-
tion. The generation and processing of miRNA from miRNA 
genes follows a defined pattern.2 Briefly, miRNAs are typi-
cally transcribed by RNA polymerase II as a primary miRNA 
(pri-miRNA) of several hundred nucleotides comprising a 
~70 bp stem-loop structure. The stem-loop structure is then 
cleaved from the pri-miRNA by a “microprocessor complex” 
formed by the RNAse III enzyme Drosha and its subunit pro-
tein DGCR8, generating the precursor miRNA (pre-miRNA), 
which is similar in structure to short hairpin RNAs (shRNAs).3,4 
The pre-miRNAs are further processed in the cytoplasm by 
the endoribonuclease Dicer, which removes the loop of the 
hairpin, yielding a miRNA duplex of ~22 bp. The antisense 
strand (targeting strand in this paper) of the miRNA duplex 
will be integrated into the RNA-induced silencing complex 
(RISC), where it blocks translation through interaction with 
its target mRNA.
The elegance and efficiency of RNA interference has 
rapidly led to knockdown vectors designed from naturally 
occurring miRNAs. A first generation of lentivectors directly 
expressed shRNAs as a simple stem loop structure with no 
flanking sequences. When transcribed, they immediately 
form a thermodynamically stable stem loop and are directly 
exported to the cytoplasm where they are processed by 
DICER bypassing Drosha. In order to express shRNAs with-
out flanking sequences, H1 (ref. 5) or U6 (ref. 6) RNA Pol 
III promoters or snRNA U1 Pol II promoters7 were initially 
used. However, these promoters suffer from (i) their constitu-
tive expression and (ii) potential toxicity due to competition 
of the artificial shRNA with endogenous miRNAs and an 
eventual subsequent saturation of the RNAi machinery, spe-
cifically the karyopherin exportin-5.8,9 Also, overexpression of 
shRNAs may stimulate the innate immune system through 
activation of the RNA-dependent protein kinase/interferon 
response.10 On the other hand, miRNA mimics are compatible 
with expression from RNA pol II tissue-specific or inducible 
promoters and produce less processed antisense/targeting 
strand RNA, which if in excess can lead to cellular toxicity.11 
Thus, constructs reproducing natural miRNA synthesis and 
processing for the purpose of gene knockdown could be pre-
ferred to shRNA constructs. Indeed, artificial pri-miRNA mim-
ics have been used for silencing a variety of target genes.12–15 
Most of these constructs were based on a naturally occurring 
miRNA miR-30 backbone with various flanking region, stem 
and loop modifications.1,12–21 A similar version of this miR-30-
based miRNA mimic is also commercially available (GIPZ & 
TRIPZ shRNAmir lentivector expression systems; Open Bio-
systems; GE Dharmacon, Lafayette, CO).
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Gene knockdown using micro RNA (miRNA)-based vector constructs is likely to become a prominent gene therapy approach. 
It was the aim of this study to improve the efficiency of gene knockdown through optimizing the structure of miRNA mimics. 
Knockdown of two target genes was analyzed: CCR5 and green fluorescent protein. We describe here a novel and optimized 
miRNA mimic design called mirGE comprising a lower stem length of 13 base pairs (bp), positioning of the targeting strand 
on the 5′ side of the miRNA, together with nucleotide mismatches in upper stem positions 1 and 12 placed on the passenger 
strand. Our mirGE proved superior to miR-30 in four aspects: yield of targeting strand incorporation into RNA-induced silencing 
complex (RISC); incorporation into RISC of correct targeting strand; precision of cleavage by Drosha; and ratio of targeting 
strand over passenger strand. A triple mirGE hairpin cassette targeting CCR5 was constructed. It allowed CCR5 knockdown 
with an efficiency of over 90% upon single-copy transduction. Importantly, single-copy expression of this construct rendered 
transduced target cells, including primary human macrophages, resistant to infection with a CCR5-tropic strain of HIV. Our 
results provide new insights for a better knockdown efficiency of constructs containing miRNA. Our results also provide the 
proof-of-principle that cells can be rendered HIV resistant through single-copy vector transduction, rendering this approach 
more compatible with clinical applications.
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Lentiviral vectors containing either shRNA or miRNA are 
very promising tools for gene therapy involving gene repres-
sion. RNA interference as a tool for gene therapy has been 
explored in vitro and in vivo using both shRNA and miRNA 
mimics. Focusing on miRNA in lentivectors, the main tar-
gets involved were HIV,22,23 hepatitis B virus,24 cancer,25 and 
Alzheimer disease,26 only to mention a few. But the stan-
dards for such vector systems are high since they should 
achieve the required knockdown effect (ideally at a single 
transgene integration level) without affecting normal cell 
functions. Indeed, multiple transgene insertions into the host 
cell genome resulting from high vector-mediated transduc-
tion rates can increase the risk of alteration of functionally 
relevant parts of the genome and in particular increase the 
risk of oncogenesis.8,27
In this study, we optimized miRNA-mimic design by adjust-
ing complementary sequences and stem lengths (mirGE). 
We then chose the most potent variant, called mirGE herein 
after, and compared it with the original miR-30 in its efficiency 
to knockdown the CCR5 HIV coreceptor. Our mirGE proved 
largely more potent than miR-30. In particular, high-through-
put sequencing revealed that mirGE is superior to miR-30 
in four aspects: yield of targeting strand incorporation into 
RISC; incorporation into RISC of correct targeting strand; 
precision of cleavage by Drosha; and ratio of targeting strand 
over passenger strand.
We increased mirGE efficiency by expressing it as a multi-
ple hairpin structure and found that a triple hairpin anti-CCR5 
mirGE downregulates CCR5 expression by more than 90% 
with a single copy of lentivector. This level of CCR5 knock-
down efficiency by a single copy of anti-CCR5 lentivector pro-
tected HeLa cells as well as primary human macrophages 
against in vitro infection with a CCR5-tropic HIV strain. To 
the best of our knowledge, this is the most efficient miRNA-
based lentivector described so far and the first demonstration 
that miRNA-based CCR5 knockdown by a single copy of a 
lentivector can confer intracellular immunization against HIV.
Our results thus pave the way toward an efficient yet clini-
cally compatible gene therapy approach aimed at generating 
HIV-resistant immune cells in human patients.
Results
Effect of miRNA hairpin features on green fluorescent 
protein knockdown
To test miRNA hairpin features critical for efficient gene 
knockdown, we constructed a lentivector containing two inde-
pendent expression units (Supplementary Figure S1). One 
unit is expressing, under the control of the human  Ubiquitin 
promoter, an mRNA containing the human microsomal gluta-
thione S-transferase 2 (MGST2) coding sequence followed 
by a variable miRNA structure targeting the green fluores-
cent protein (GFP) living color. The MGST2 gene was used 
as spacer as we initially observed that repression activity 
was dramatically reduced when miRNAs were placed imme-
diately after the transcription start site (data not shown). A 
similar finding has been reported that absence of intervening 
sequence between the 5′ end of the mRNA and miRNA hair-
pin was detrimental to knockdown activity.12 The other unit 
is expressing the mCherry living color under the control of 
the human phosphoglycerate kinase 1 promoter. This dual 
cassette design allowed us to reliably follow transduced cells 
expressing constant amounts of red mCherry protein, while 
GFP expression was downregulated by the miRNA.
We then transduced a clone of HeLa cells stably expressing 
GFP (4.5 cells),28 with lentivectors containing seven versions 
of a composite miRNA backbone containing the same 22 
nucleotide segment targeting the GFP living color  (Figure 1). 
This miRNA backbone contains the miR-16 lower stem as 
well as flanking regions, the target-specific stem containing 
a wooble at position +12 (as in miR-16) and the miR-30 loop. 
We kept the miR-30 loop since the terminal loop seems to 
be dispensable for pri-miRNA processing.4 Variations on this 
backbone were made in order to test for two features, i.e., 
the length of the lower stem and the side of the mismatch on 
the targeting strand. D13M5 refers to a 13 bp long lower stem 
and a single nucleotide mismatch at the 5′ end of the target-
ing strand and is thus analogous to miR-16 (ref. 4) in terms 
of lower stem length and targeting strand mismatch orienta-
tion. Other hairpin designs follow the same numbering code, 
where the number after D represents the length of the lower 
stem, and the number after M represents the mismatched 
end of the targeting strand. GFP-positive 4.5 cells were trans-
duced with similar multiplicity of infections (MOIs) of each 
vector, and the percentage of GFP-negative cells generated 
within the total of mCherry-positive transduced cells was 
analyzed by flow cytometry (Figure 1b). Percentages were 
then plotted for statistical analysis (Figure 1c). The most 
obvious observation is that the length of the lower stem is 
critical for overall efficiency, as hairpins with 13 or 15 nucleo-
tides in their lower stem were the most potent at generating 
GFP-negative cells. Longer (D17) or shorter (D11, D9) stem 
lengths show negligible effect on GFP downregulation. Such 
an impact of lower stem length on knockdown efficiency was 
reported previously15 and is likely due to the generation by 
Drosha processing of hairpins with lengths that are inappro-
priate for further steps in RISC processing.29 Indeed, it was 
shown that the Drosha cleavage site is determined mostly by 
the junction between the flanking sequences and the lower 
stem and that cleavage occurs ~11 bp (when counting on the 
bottom strand, i.e., 13 bp on the top strand as we number 
in this paper) up from this junction.4 Comparison of D13M5 
and D13M3 shows a difference; however, it is not statistically 
significant. Increasing the number of experiments may reveal 
a significant difference which will be in accordance with the 
current understanding of preferential strand incorporation 
into RISC.30,31 We thus chose the D13M5 hairpin (hereinafter 
called mirGE) as the best miRNA configuration to compare 
to the miR-30 hairpin in knockdown experiments targeting 
CCR5.
Effect of targeting sequence and hairpin context on 
CCR5 knockdown
We then compared the efficiency of mirGE and miR-30 hair-
pin (for details, see Figure 2), context for the knockdown of 
a second target gene, namely CCR5. Two CCR5-targeting 
sequences, T1 and T7, were identified in silico (see Supple-
mentary Material). The T7 target sequence has also previ-
ously been described as a very potent target.32 T1 and T7 
were cloned as a single hairpin in either the miR-30 or miGE 
www.moleculartherapy.org/mtna
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backbones. As shown in Supplementary Figure S3, the 
lentivector expression cassette transcribes a single mRNA 
that encodes for the GFP living color followed by the CCR5-
targeting miRNAs.  Lentivectors are then used to transduce 
a clone of HeLa cells constitutively expressing CCR5 (HR5 
cells), and CCR5 knockdown is measured in GFP-positive 
transduced cells  (Figure 3a). We found that both T1 and T7 
targeting sequences were much more efficient in downregu-
lating CCR5 in the mirGE than that in the miR-30 backbone 
(Figure 3b) and that T7 was superior to T1 in the same 
hairpin context.
Note that the mean fluorescence intensity (MFI) of GFP 
decreases more in parallel with the knockdown efficiency 
(Figure 3, in particular in mirGE-transduced cells). This is due 
to the fact that—in this construct—the hairpins are within the 
3′UTR of the mRNAs coding for GFP (see  Supplementary 
Figure S3). Therefore, efficient miRNA processing removes 
poly-A tail leading to destabilization of mRNAs coding for 
GFP.33 A similar finding was described by Sun et al.20
This set of experiments indicates that T7 is a better CCR5 
target than T1 and that the mirGE backbone is more effi-
ciently processed by Drosha than the miR-30 backbone.
Figure 1 Downregulation of GFP in 4.5 cells using lentivectors expressing various anti-GFP miRNAs constructs. (a) Schematic 
diagram of variations introduced in the miRNA design, based on features described in Supplementary Figure S2. (b) FACS plots 
representative of independent experiments: control, D9M3, D9M5, D11M5, and D13M3 (n = 4), D13M5 (n = 7). D15M5, D17M5 (n = 3). 
4.5 GFP expressing cells were transduced with equivalent quantities of lentivectors expressing mCherry alone (GFP control, upper plot), 
or mCherry together with the corresponding miRNA hairpin displayed alongside in panel a. For analysis, FACS plots were analyzed using 
quadrants to delineate Cherry-positive transduced cells. Then, the ratio was calculated as the fraction of GFP-negative/Cherry-positive 
cells over the total of Cherry-positive cells. (c) Bar graph diagram corresponding to the different experiments as illustrated in the FACS plots 
alongside in panel b, showing the percentage of GFP-negative cells within total Cherry-positive cells for each corresponding miRNA design. 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, using one-way ANOVA followed by Bonferroni’s mulitple comparison test. ANOVA, analysis 
of variance; GFP, green fluorescent protein; miRNA, micro RNA.
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Effect of miRNA backbone and hairpin number on CCR5 
knockdown
We then analyzed the knockdown potential of T7 targeting 
sequence in HR5 cells when miRNA hairpins are expressed 
as multiple copies on a single mRNA, either in miR-30 or 
mirGE context. For this, we used a system that allowed us to 
clone several copies of miRNA hairpins in tandem in a single 
lentivector backbone. This strategy, depicted in Supplemen-
tary Figure S3, is largely inspired from Sun et al.20
Since our ultimate goal is to apply miRNA-based gene 
silencing for clinical applications, we analyzed experiments 
performed in conditions which represent the safest trans-
duction rate for gene therapy, i.e., one copy of transgene 
per cell. According to Poisson’s law, when less than 20% 
of cells are transduced, the majority of transduced cells 
contain only one copy of the lentivector transgene. So, not 
only it reproduces the most desirable situation for clinical 
application but also it facilitates the comparison of different 
constructs between each other.
We first assessed the efficiency of the miR-30 backbone 
containing one or two T7 constructs (Figure 4). They gave 
unsatisfactory results with a knockdown of CCR5 of 16 and 
33%, respectively. In contrast, a single hairpin of T7 in the 
mirGE context was already more efficient than two cop-
ies of miR-30 with a knockdown of 45 compared with 33%. 
Increasing the numbers of hairpins in mirGE to two or three 
resulted in 80 or 91% knockdown, respectively.
As observed in Figure 3, higher knockdown efficiency 
of mirGE backbones was correlated with a more important 
decrease in GFP fluorescence as measured by MFI of GFP, 
again suggesting that a better Drosha processing results in 
fewer copies of translatable mRNA. When the mRNA only 
contains the GFP coding sequence, GFP MFI is 195. When 
containing GFP and one copy of miR-30 hairpin, the GFP MFI 
drops to 99 and when containing GFP and one copy of mirGE, 
GFP MFI drops to 36. From this, one can estimate that only 
50% of all mRNA containing one miR-30 hairpin is processed 
and available for RNA interference, whereas when one copy 
of mirGE is present, more than 80% of mRNAs are processed 
and available for RNA interference.
High-throughput sequencing of mirGE and miR-30 small 
RNA products
The lower Drosha processing of miR-30 could suffice to 
account for its lower knockdown efficiency as compared 
with mirGE. However, another scenario can also contribute 
to the lower efficiency of miR-30. As discussed for Figure 
1, if Drosha processes miR-30 after ~13 bp of lower stem 
structure, it will generate a targeting strand that will miss 
two nucleotides complementary to the target sequence at 
Figure 2 Schematic representations of miR-30 and mirGE designs. (a) miR-30 design as it has been previously described.1,14,17 Main 
features include 11 bp lower stem, upper double-strand stem composed of the fully complementary targeting strand (bottom strand, dotted 
line), 3′ mismatch of targeting strand as well as a weak AU bond on the 5′ of the targeting strand. (b) mirGE backbone developed in this study. 
Main features include miR-16 flanking regions, upper double-strand stem composed of the fully complementary targeting strand (top strand, 
dotted line), a 13 bp lower stem, a wobble at position 12 of the upper stem (position 1 is the first 5′ base of the targeting strand), a 5′ mismatch, 
and no 3′ mismatch on the targeting strand.
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b
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its 3′ end and will also have an extra AU artificial sequence 
at its 5′ end (Figure 2a).
To investigate this cleavage issue, we performed a high-
throughput sequencing analysis of the small RNAs gen-
erated by miR-30 and mirGE constructs. As described in 
Materials and Methods, we purified 15 to 40 nucleotide long 
fragments before sequencing, in order to analyze mostly 
RNAs that are incorporated into RISC. The raw counts of 
reads from this sequencing are shown in Supplementary 
Table S1 and can also be downloaded as described in 
Materials and Methods. As shown in Supplementary Table 
S2, the percentage of reads assigned to either miR-30 or 
mirGE are comparable, i.e., 2.33 versus 2.21%, respec-
tively. Since mirGE cells are transduced at 23% and miR-
30 cells are transduced at 43%, and according to Poisson’s 
law, the average copy number in mirGE cells can be esti-
mated at 0.23, whereas the average copy number in miR-
30 cells can be estimated at more than 0.4. This indicates 
that mirGE can produce approximately two times more tar-
geting strands than miR-30. This is in accordance with GFP 
intensities observed in Figure 4, suggesting that Drosha 
cleavage is more efficient on mRNAs containing mirGE 
hairpins than on mRNAs containing miR-30 hairpins.
Moreover, the percentage of reads where the targeting 
strand has an incorrect start position is 7.53 for miR-30 and 
0.16 for mirGE, indicating that overall processing of RISC-
incorporated targeting strands is ~50 times better for mirGE 
than that for miR-30. This is confirmed in the mirGE_triple 
sample, where the transduction rate is high, 90% positive 
cells corresponding to an estimated average copy number of 
more than five. In this case, even though the reads assigned 
to mirGE represent more than two-thirds of all cellular reads 
(69.8%), the percentage of reads with an incorrect start posi-
tion is even lower than in mirGE_single (0.06 versus 0.16%, 
respectively). This suggests that the mirGE backbone can be 
processed with higher efficiency and higher precision than 
miR-30, even when representing the majority of all Drosha-
processed miRNAs. We further investigated the issue of 
cleavage accuracy for the mirGE or miR-30 backbone. As 
shown in Figure 5, the Drosha cleavage occurs at the correct 
position both in mirGE and miR-30 although the accuracy 
with which this occurs is very different when comparing the 
Figure 3 Downregulation of CCR5 in HR5 cells using lentivectors expressing different anti-CCR5 miRNA target sequences in 
different hairpin contexts. (a) FACS plots showing representative data from three independent experiments performed with three 
independent lentivector preparations. HR5 cells were transduced with lentivectors expressing either GFP alone (GFP control vector, not 
shown) or GFP followed by miR-30 or mirGE hairpins containing the T1 or the T7 targeting sequence (see Results and Materials and Methods 
for details). For determination of MFI (mean of fluorescence intensity) of transduced versus untransduced cells, square gates were used by 
default, and polygonal gates were used when populations were overlapping in one or two axes. MFI of GFP for the transduced population (R3) 
for the miR-30 T1 condition was: 150 (percentage transduction 66%), miR-30 T7 condition: 103.5 (percentage trandsuction 46%), mirGE T1 
condition: 47.8 (percentage transduction 48%), and mirGE T7 condition: 30.4 (percentage transduction 23%). (b) Bar graph analysis of data 
in a. CCR5 downregulation was calculated by dividing the CCR5 MFI value of GFP-positive cells (transduced cells, gate R3) by the CCR5 MFI 
value of GFP-negative cells (untransduced cells, gate R2), within each sample. This allows for compensation of sample-to-sample variations 
due to slight changes in CCR5 antibody-to-cell ratios. The relative CCR5 expression in transduced cells was then displayed as percentage 
of CCR5 expression normalized to the internal control provided by untransduced cells. Values represent average from n = 3 independent 
experiments. ***P < 0.001, ****P < 0.0001 using one-way ANOVA followed by Bonferroni’s mulitple comparison test. ANOVA, analysis of 
variance; GFP, green fluorescent protein.
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two backbones (discussed below). This is surprising for miR-
30 since its lower stem is two nucleotides shorter than that 
usually seen in miRNAs.4 Also, Dicer cutting occurs mostly 
at the expected site so the vast majority of the reads covers 
the targeting strand, whether it is generated by mirGE or by 
miR-30.
However, this analysis identified two further points where 
mirGE was superior to miR-30. First, there is a 10-fold dif-
ference in the ratio of RISC incorporation of targeting ver-
sus passenger in favor of mirGE over miR-30. As shown in 
Supplementary Table S1 and Figure 5, for mirGE_single 
sample, there is a count of 18,253 reads at position 26 versus 
no read at position 65 or around. Thus, a ratio of 14,823 could 
only be calculated with the mirGE_triple sample (2,638,464 
reads starting at position 26 over 178 reads starting at posi-
tion 65). For miR-30, there are 44,853 reads of starting at 
position 72 over 33 reads starting at position 33, giving a 
ratio of targeting strand/passenger strand of 1,359. Second, 
Drosha cutting is 500–1,000-fold more precise in mirGE than 
that in miR-30. As shown in Supplementary Table S1 and 
Figure 5, for mirGE_single sample, there is a count of 18,253 
reads at position 26 and a total of five reads proximal but 
outside position 26, giving a ratio of 0.00027 of incorrect cuts. 
A similar ratio was obtained from the mirGE_triple sample, 
Figure 4 Downregulation of CCR5 in HR5 cells using lentivectors containing various copies of different anti-CCR5 miRNA constructs. 
(a) FACS plots showing representative data from four independent experiments (n = 4). HR5 cells were transduced with various concentrations of 
lentivectors expressing either GFP alone (GFP control vector) or GFP followed by one or several copies of a given miRNA backbone containing 
the T7 targeting sequence. The T7 targeting sequence was inserted in one or two copies in the miR-30 context, and in one, two, or three copies 
in the mirGE context. For further analysis, only FACS plots displaying less than 20% transduced cells (hence mostly single-copy GFP-positive 
cells) were retained. For determination of MFI (mean of fluorescence intensity) of transduced versus untransduced cells, square gates were used 
by default and polygonal gates were used when populations were overlapping in one or two axes. MFI of GFP for the transduced population (R3) 
for the GFP control condition was: 195.7 (percentage transduction 38.3%), miR-30 single: 98.8 (percentage transduction 7.6%), miR-30 double: 
62.37 (percentage transduction 19.7%), mirGE single: 36 (percentage transduction 13.7%), mirGE double: 18.5 (percentage transduction 
7.1%), and mirGE triple: 12.9 (percentage transduction 9.1%). (b) Bar graph analysis of data in a. CCR5 downregulation was calculated as 
described in Figure 3. The relative CCR5 expression in transduced cells is displayed as percentage of CCR5 expression normalized to internal 
control untransduced cells. Values represent average from n = 4 independent experiments. ****P < 0.0001 using one-way ANOVA followed by 
Bonferroni’s mulitple comparison test. ANOVA, analysis of variance; GFP, green fluorescent protein.
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with 2,638,464 reads at position 26 and a total of 1,194 reads 
proximal but outside position 26, giving a ratio of 0.00045. Of 
note, even when reads are coming from mirGE processing 
of a triple hairpin and amount to more than two-thirds of all 
trimmed reads, Drosha still manages to be extremely accu-
rate in mirGE processing. On the contrary, miR-30 process-
ing by Drosha is 500–1,000 times less precise with a ratio of 
0.21 of incorrect cuts (33 reads at position 33 and 7 reads at 
position 34). When applying this calculation to Dicer process-
ing, miR-30 appears to be processed with an accuracy that 
is six times higher than that for mirGE, with ratios of incorrect 
cuts of 0.08 and 0.49, respectively. Such a difference is hard 
to explain since both hairpins have the same loop to present 
to Dicer.
Taken together, this high-throughput sequencing analy-
sis shows that mirGE is superior to miR-30 in four aspects: 
yield of targeting strand incorporation into RISC; percent-
age of RISC-incorporated targeting strands with the correct 
sequence; precision of cleavage by Drosha; and ratio of tar-
geting strand over passenger strand. It thus provides molecu-
lar basis to account for the superiority of mirGE over miR-30 
in knockdown efficiency.
Figure 5 High-throughput sequencing of short RNAs generated by miR-30 and mirGE and miRNA constructs. (a) Schematic diagram 
of the miR-30 miRNA containing the CCR5 T7 target. Targeting strand is in red (bottom strand). Position and numbering of reads major starts 
and reads major ends of coverage (see Supplementary Table S1 for details) are indicated by arrows. (b) Schematic diagram of the mirGE 
miRNA containing the CCR5 T7 target. Targeting strand is in red (top strand). Position and numbering of reads major starts and reads major 
ends of coverage (see Supplementary Table S1 for details) are indicated by arrows. (c) Coverage plot of reads aligning to the targeting 
strands of miR-30 or mirGE hairpins sequences. Base 1 corresponds to nucleotide 72 for miR-30 and to nucleotide 26 for mirGE. (d) Summary 
of analysis of reads covering the targeting or passenger strand sequences (see text and Supplementary Table S1 for details).
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Figure 6 Resistance to R5-tropic HIV infection of HR5 cells transduced with anti-CCR5 mirGE lentivector. (a) Representative images 
of control parental HeLa cells (HeLa), untransduced HR5 (HR5), HR5 cells transduced with a lentivector expressing GFP alone (GFP), and 
HR5 cells transduced with a lentivector expressing GFP and three hairpins of anti-CCR5 mirGE (mirGE). Pictures of these four cell lines 
were taken at day 0, day 5, and day 7 of HIV-R5 infection. Only parental HeLa cells and mirGE-transduced cells survive the infection. Note 
that mirGE 1 µl indicates cells transduced with the lowest volume of vector corresponding to a 7% transduction rate. (b) Values of HIV p24 
antigen in supernatants of cells showed in Figure 6a, collected over 6 days post-R5 HIV infection. (c) Values of HIV p24 antigen collected 
over 6 days post-R5 HIV infection, in supernatants of mirGE cells that survived the first HIV challenge in Figure 6b. Negative and positive 
controls for HIV replication were provided by naive HeLa and HR5 cells, respectively. (d) Values of HIV p24 antigen collected over 6 days 
post X4 HIV infection, in supernatants of mirGE cells that survived the first and second HIV challenges in Figure 6b,c. Negative control for 
X4 HIV infection was provided by naive CD4-negative parental HeLa cells and a fresh batch of naive HR5 cells served as the positive control 
for infection. (e) Phenotypic analysis of HR5 cells transduced with GFP control lentivector (no miRNA). (f) Phenotypic analysis of HR5 cells 
transduced with GFP-anti-CCR5 mirGE lentivector prior to R5-tropic HIV infection. Within the untransduced cells in gate R2 (89%), the CCR5 
and GFP MFIs are 144 and 2.4, respectively. Within the transduced cells in gate R3 (6%), the CCR5 and GFP MFIs are 14 and 18, respectively. 
(g) Phenotypic analysis of HR5 cells from (F) 7 days post infection with R5-tropic HIV. The majority of cells (81%) are CCR5-negative. The 
CCR5 and GFP MFIs in this population (gate R3) are 3 and 48, respectively.
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Effect of CCR5 knockdown on HIV infection in vitro
Finally, we wanted to determine whether the CCR5 knock-
down induced by transduction of cells with a single copy of 
lentivector containing an optimized anti-CCR5 miRNA design 
was efficient enough to render cells resistant to HIV infec-
tion. For this, we used a HIV-permissive clone of HeLa cells 
expressing both CD4 and CCR5 (HR5 cells, see Materials 
and Methods section). We transduced the HR5 cells with 
varying amounts of lentivectors, containing GFP and triple 
hairpin anti-CCR5 mirGE, or GFP only as negative control 
(Figure 6a). Again, we included a condition with ≤20% of the 
cells transduced (mirGE 2 µl = 13% and 1 µl = 6%), hence 
observing the effect of single-copy transgene expression. 
Cells were seeded at 20% confluence 1 day prior to infection 
with the CCR5 tropic HIV strain, YU-2. All cells which were 
either mock-transduced or transduced with the GFP control 
lentiviral vector were either dead or showed massive syncy-
tia induction 5 days postinfection (Figure 6a). In contrast, 
a subpopulation of the cells previously transduced with the 
anti-CCR5 mirGE lentivector survived the HIV infection and 
further proliferated. Monitoring of the HIV p24 antigen in the 
supernatants reflected the microscopic findings with lower 
levels of p24 antigen in the cells transduced with the anti-
CCR5 mirGE (Figure 6b). At day 5, we observed syncytia 
induction in close proximity to apparently healthy cells. At day 
7, the positive selection for the HIV resistant cells is evident. 
Phenotypic analysis of these surviving cells shows that they 
have lost CCR5 expression (Figure 6g). The cells which sur-
vived this first infection with R5-tropic HIV were rechallenged 
with the same HIV strain. Corroborating our observation that 
these cells have lost CCR5 expression, they were entirely 
HIV resistant (Figure 6c). Finally, we wanted to verify that 
the two rounds of R5-tropic HIV infection did not select for 
cells that were resistant to HIV infection in general. For this, 
we infected the surviving cells with an X4-tropic HIV strain. 
As shown in Figure 6d, these cells can support X4-tropic 
HIV replication at the same level as naive HR5 cells. Thus, 
no nonspecific HIV resistance appears to have developed 
in the process. We also performed a phenotypic analysis of 
cells that survived R5-tropic infection and compared them 
with the subpopulation of cells transduced with the anti-
CCR5 lentivector before infection. As shown in Figure 6f, the 
transduced cells represent 6% of the total population, which 
implies that the vast majority contain only one copy of the 
transgene. When compared with the internal negative control 
provided by the untransduced cells whose CCR5 MFI is 114, 
the knockdown ratio is more than 10-fold, as also shown in 
Figure 4b. The same phenotypic analysis performed 7 days 
after HIV R5 infection shows a dramatic enrichment, yielding 
to a population where CCR5 expression is virtually absent 
(Figure 6g).
To further check if our anti-CCR5 lentivector could inhibit 
HIV infection in natural target of the virus, we performed 
HIV-R5 infection in human monocyte-derived macrophages 
(MDMs) with or without prior transduction with the anti-CCR5 
T7 triple hairpin lentivector described above. MDMs were 
matured in culture for 8 days as described in the Materials 
and Methods section. In order to maximize R5-tropic HIV 
infection, MDMs were treated with VPX-virus-like particles 
for 2 hours prior to transduction, as described previously.34
 
The MDMs were then transduced with various quantities of 
either a control GFP vector or the anti-CCR5 lentivector, fol-
lowed by infection with R5-tropic HIV-luciferase virions after 
4 days (see Materials and Methods for details). As shown 
in Figure 7, we can see a strong inhibition of HIV infection 
using anti-CCR5 lentivector at a MOI of 1.7. Other conditions 
using lentivectors, i.e., lower MOI of anti-CCR5 lentivector 
or control GFP lentivector, display a moderate inhibition of 
HIV infection, as compared with the no vector condition. This 
is most likely due to the triggering by defective particle of 
cell-autonomous innate immune systems independent of 
SAMHD1 (see ref. 35 for review).
Altogether, these data show that our anti-CCR5 lentivector 
can efficiently block HIV infection at low copy number in both 
artificial and natural target cells.
Figure 7 Resistance to R5-tropic HIV infection of monocyte-
derived macrophages (MDMs) transduced with anti-CCR5 
mirGE lentivector. (a) Bar graphs showing the level of infection of 
MDMs by recombinant R5-tropic HIV particles encoding luciferase 
(see Materials and Methods for details). Prior to infection, MDMs 
were either not transduced (no vector) or transduced with various 
amounts of anti-CCR5 mirGE lentivector (CCR5 KD) or with a 
control vector expressing only GFP (GFP). Vector stocks (CCR5 
KD and GFP) were normalized and 1 µl of vector corresponds to a 
MOI of 1.7. Experiments consisted of a minimum of three technical 
replicates. Luciferase activity: no vector 1,250 (SEM ± 248), 0.1 µl 
CCR5 knockdown (KD) vector 811 (SEM ± 195), 0.1 µl GFP vector 
711 (SEM ± 137), 1 µl CCR5 KD vector 69 (SEM ± 44), and 1 µl GFP 
vector 791 (SEM ± 18). P values (**P < 0.0099, **P < 0.0038, and 
***P < 0.0004) were obtained using a two-tailed unpaired t-test. (b,c) 
Light microscope images of macrophages 4 days posttransduction 
with 1 µl of anti-CCR mirGE vector or 1 µl of GFP vector, respectively 
(×20 magnification).
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Discussion
The work presented here is the result of an ambitious goal: 
efficient gene knockdown with a single copy of miRNA-con-
taining lentivector. We could achieve this goal by optimization 
of critical miRNA features, combined with multimerization of 
miRNA hairpins in a single cassette. When applied to human 
CCR5, we reached a knockdown efficiency which provides 
the ground for a clinically applicable approach toward cellular 
immunization against HIV.
When we designed our knockdown lentivector constructs 
by implementing the miR-30 protocols from institutional 
online tools (http://hannonlab.cshl.edu), these constructs 
hardly reduced the level of CCR5 expression by one-third 
(Figure 3, miR-30 T1 and miR-30 T7). This was surprising 
and disappointing since T7 has been described as one of the 
most potent CCR5 RNAi targets.32 Notably, cells with mul-
tiple copies of anti-CCR5 T7 miR-30 did show efficient CCR5 
knockdown. Clearly, one cannot expect any phenotype with 
this level of knockdown and therefore no clinical applicability.
A careful review of articles about Drosha processing and 
RISC incorporation identified three potential features critical 
for optimal miRNA-based silencing: (i) length of the lower 
stem for optimal Drosha processing, (ii) destabilization of the 
5′ end of the targeting strand for optimal RISC incorporation, 
and (iii) a mismatch in the middle of the upper stem to avoid 
abortive processing by Drosha.4,12,15,19,20,36–38
When these three features were incorporated in our mirGE 
hairpin design, the knockdown efficiency improved dramati-
cally compared with miR-30-based hairpin designs, whether 
we targeted GFP or CCR5 (Figures 1 and 3). The level of 
knockdown with a single mirGE hairpin construct, however, 
still did not reach a level of downregulation compatible with 
clinical applications, i.e., >90%. We reached this threshold by 
tandem addition of hairpins, achieving 90% knockdown with 
a single copy of a lentivector containing a triple anti-CCR5 
mirGE construct (Figure 4). These tandem repeats do not 
seem to be subject to recombination (data not shown) and 
are thus a safe alternative to the accumulation of integrated 
proviral copies in the target cell genome.
To investigate the mechanisms underlying the superior-
ity of mirGE over miR-30, we performed a high-throughput 
sequencing of short RNAs generated by the two miRNA 
backbones (Figure 5). We found that mirGE performed bet-
ter than miR-30 in terms of yield of targeting strand incorpo-
ration into RISC as well as percentage of correct targeting 
strands incorporated into RISC. Also, the ratio of targeting 
strand over passenger strand is higher for mirGE than that 
for miR-30. We also found that Drosha cutting on miR-30 
was quite imprecise, with 21% of cuts outside of the correct 
position. On the contrary, Drosha cutting on mirGE was very 
precise (500–1,000-fold more precise than that for miR-30) 
and keeps the same level of accuracy even when mirGE is 
expressed at high levels and in a triple hairpin context.
Surprisingly, Dicer cutting was not very precise, rang-
ing from 8 to 49% of incorrect cuts for miR-30 and mirGE, 
respectively. This level of inaccuracy is comparable to Drosha 
cutting on miR-30 (21%). One possibility is that the miR-30 
loop that we kept in our mirGE design is also not optimal. 
We plan on testing other loop sequences based on features 
affecting enzymatic processing of hairpin transcripts as 
described elsewhere.39
Taken together, our results show a clear superiority of 
mirGE over miR-30 in terms of processing, cleavage accuracy, 
targeting strand incorporation, and, most of all, knockdown 
efficiency. Also, in mirGE, the upper strand is incorporated 
in RISC, whereas in miR-30, it is the lower strand. In mirGE, 
Drosha cutting generates the 5′ end of the guide strand and 
is extremely precise, whereas in miR-30, the terminal loop 
processing, whether done by Dicer or single-strand RNAses, 
generates the 5′ end of the guide strand and is imprecise and 
requires further optimization. Finally, in the meantime, we 
have applied the mirGE design to other target genes (Caveo-
lin-1, VEGF, and Wnt5a, data not shown) and found equally 
efficient knockdown efficiency, allowing gene repression at 
low copy number. We thus propose to use the mirGE design 
as default design for miRNA-based knockdown applications.
Using a triple anti-CCR5 mirGE construct to protect Hela 
R5 cells against HIV infection in vitro, we showed that a 
subpopulation of cells transduced at levels lower than 10%, 
hence mostly containing only one copy of anti-CCR5 mirGE,27 
could resist HIV R5 infection (Figure 6). Rechallenging these 
surviving cells with HIV R5 did not show any virus replica-
tion, whereas the same cells remained permissive to HIV 
X4 infection, proving the specificity of the anti-CCR5 cellular 
immunization. To further validate the protective effect of our 
anti-CCR5 constructs, we tested it in natural targets of HIV 
R5, i.e., human macrophages (Figure 7). We found that our 
construct, even at low MOI, efficiently and specifically pro-
tected macrophages against HIV-R5 infection. This protective 
effect in primary human cells was later confirmed in human-
ized mice (Myburgh et al., manuscript in preparation).
Altogether, these results can be compared in terms of effi-
ciency to the work of Ringpis et al.40 However, they used an 
shRNA-based vector which may be less desirable for clinical 
application due to potential adverse effect of shRNA-related 
toxicity.8,9,11
In conclusion, this work provides the ground to ultimately 
build a genetic tool that can be used to confer HIV resistance in 
patients. Also, the efficiency of our system provides a universal 
tool to knockdown any clinically relevant target gene without 
sacrificing safety by requiring multiple transgene integrations. 
Finally, we provide here an algorithm (see Supplementary 
Material) as well as a set of genetic tools for everyone to 
design “optimized” miRNA against any target gene.
Materials and methods
Construction of miRNA-containing plasmids and lentiviral 
vectors. To construct the plasmid intermediates contain-
ing the various miRNA hairpins, we followed a protocol 
largely inspired by Sun et al.20 with the following modifica-
tions. An amplicon containing the miRNA hairpin flanked by 
sequences for digestion with restriction enzymes was gen-
erated by high-fidelity PCR using Herculase II polymerase 
(Agilent, Santa Clara, CA). The oligos for PCR template and 
primers were obtained from Microsynth (Balgach, Switzer-
land) and then Sigma (St Louis, MO). The templates for miR-
30 hairpins had inside sequences specific for gene targeting 
www.moleculartherapy.org/mtna
Optimization of miRNA Features for Gene Knock-down
Myburgh et al.
11
and common outside sequences for annealing with miR-30 
primers (see Supplementary Material). The mirGE hair-
pins were amplified from similar templates but with common 
outside sequences for annealing with mirGE primers (see 
Supplementary Material). PCR products were digested 
with BamHI and XbaI restriction enzymes (New England Bio-
labs, Ipswich, MA) and ligated into a pENTR-derived plas-
mid (Invitrogen) using BamHI and XbaI sites located directly, 
either downstream of the MGST2 gene (Genbank Access: 
U77604.1) for miRNAs targeting GFP (see Supplementary 
Figure S1a) or downstream of the GFP gene for miRNAs 
targeting hCCR5 (Supplementary Figure S3a). Ligation 
was performed using T4 DNA ligase (New England Biolabs). 
The pENTR-GFPmir plasmid maps and sequences are avail-
able at our institutional website (http://lentilab.unige.ch). The 
amplicon parts of each clone were verified by sequencing. 
For constructs containing multiple hairpins, PCR products 
were inserted using BamHI and SpeI sites as depicted in 
Supplementary Figure S3a and described before by Sun 
et al.20 (CCR5 knockdown). This allows for the insertion of 
multiple miRNAs where each new addition was verified by 
sequencing. The final lentivector plasmid was generated by 
an LR Clonase II (Invitrogen, Carlsbad, CA)-mediated recom-
bination of a pENTR plasmid containing the human ubiquitin 
promoter (pENTR-L4-UBI-L1R) and a pCLX-R4-DEST-R2 
lentivector destination cassette (Supplementary Figures 
S1b and S3b). For GFP knockdown experiments, a specific 
lentivector destination cassette (pCWX-R4-DEST-R2-PC) 
was used, containing an additional transcription unit with 
the human  phosphoglycerate kinase 1 promoter driving the 
mCherry living color, as described in the text. All maps and 
sequences of the plasmids used in this study are available 
at our institutional website (http://lentilab.unige.ch). The GFP 
target sequence—AAGAACGGCATCAAGGTGAACT—was 
taken from previous publication.41 The human CCR5 (Gen-
bank NM_000579.3) target sequences were chosen using the 
online web server at http://rna.tbi.univie.ac.at/cgi-bin/RNAxs 
and from previously published article.32 The two CCR5 target 
sequences retained were named target 1 (T1) 5′-TTTCCATA-
CAGTCAGTATCAAT and target 7 (T7) 5′-AAGTGTCAAGTC-
CAATCTATGA. Sequences of templates for various anti-GFP 
miRNA, anti-CCR5-T1, and anti-CCR5-T7, used for PCR 
amplification, as well as the full algorithm used to design opti-
mized upper and lower strands, are given in Supplementary 
Material section.
Lentiviral vector production and titration. Lentiviral vector 
stocks were generated using transient transfection of HEK 
293T/17 cells with the specific lentivector transfer plasmid, 
the psPAX2 plasmid encoding gag/pol and the pCAG-VSVG 
envelope plasmid, as previously described.42,43 Lentivector 
titer was performed using transduction of HT-1080 cells fol-
lowed by flow cytometry quantification of GFP-positive (or 
mCherry positive) cells 5 days after infection, as previously 
described.42,43
Cell culture and knockdown analysis. All cell lines were cul-
tured in high-glucose Dulbecco’s modified eagle medium 
(Sigma) supplemented with 10% fetal calf serum, 1% 
Penicillin, 1% Streptomycin, and 1% l-glutamine. For GFP 
knockdown studies, the 4.5 cell line28 containing one copy 
of a GFP-expressing lentivector was used. For each knock-
down assay, cells were analyzed 5 days after transduction. 
For CCR5 knockdown studies, a subclone of Hela-derived 
TZM-bl cells (AIDS Repository, Germantown, MD), express-
ing CD4 and high levels of human CCR5, named here HR5, 
was used. CCR5 and CD4 quantification was performed 
using an APC and PE Cy7-labeled antibody, respectively (BD 
Pharmingen Cat. 550856; Franklin Lakes, NJ, Biolegend Cat. 
300511; San Diego, CA), followed by flow cytometry analysis 
using FACS Vantage (Becton Dickinson, Franklin Lakes, NJ) 
or MoFlow Astrios (Beckman Coulter, Brea, CA).
High-throughput sequencing of miRNA cleavage products. 
The samples were processed following the illumina TruSeq 
Small RNA protocol (www.illumina.com). In short, total RNA 
(2 µg per sample) from R5 cells transduced with lentivec-
tors expressing either mirGE-T7 or miR-30 T7 miRNAs was 
extracted using TRIzol (Life Technologies, Carlsbad, CA). After 
validation of RNAs, 1 µg of total RNA from each sample was 
ligated to specific 3′ and 5′ adapters. In a subsequent reverse 
transcription step, single-stranded cDNA was generated, fol-
lowed by PCR amplification and gel purification that selecting 
constructs holding specific RNA fragments with an approxi-
mate length of 22 nucleotides (range: 15–40). Reads were 
sequenced on the illumina HiSeq platform with a length of 
50 bp. Partial adapter sequences were trimmed using Flexbar 
v2.4 (http://sourceforge.net/projects/flexbar/?source=navbar). 
The trimmed reads were aligned to the hairpin sequences of 
miRBase v20 (http://www.mirbase.org) and the sequences 
of the mirGE and miR-30 constructs. Alignment was done 
with Bowtie with the options “--chunkmbs 1024 -e 50 -a -m 
50 --best --strata --nomaqround –y”. We counted only the 
number of reads that aligned to the positive strand of the 
sequences. Raw data of this study have been uploaded to the 
European Nucleotide Archive and can be accessed at this link: 
http://www.ebi.ac.uk/ena/data/view/PRJEB7175.
R5-tropic and X4-tropic HIV infection of HR5 cells. Viral 
stocks were obtained by polyethylenimine-mediated transfec-
tion (Polysciences, Warrington, PA) of 293T cells with pYU-2 
or pNL4-3 (provided through the NIH AIDS Research and 
Reference Reagent Program). Forty-eight hours after trans-
fection, virus was harvested, filtered (0.45 µm), and frozen 
at −80 °C until use. Virus titers were determined as previ-
ously described.44 Briefly, TCID50 (tissue culture infectious 
dose 50%) was determined by infecting human CD8+T cell 
depleted peripheral blood mononucleated cell from three 
donors which were stimulated by PHA and anti-CD3 beads 
(Dynal 11131D; Life Technologies). Then, viral stocks were 
adjusted to 1 × 106 TCID50/ml, aliquoted, and frozen at −80 
°C before use. HR5 cells were infected for 6 hours at an MOI 
of 2.5, washed three times with phosphate-buffered saline, 
and then cultured in Dulbecco’s modified eagle medium 
(Invitrogen) with 10% fetal calf serum (PAA Laboratories, 
Piscataway, NJ), 1% Penicillin/Streptomycin (Invitrogen Life 
Technologies), and 1% l-glutamine (Invitrogen Life Technolo-
gies). Assays for HIV p24 antigen levels in cell culture super-
natants were performed using an in-house enzyme-linked 
immunosorbent assay as previously described.45
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R5-tropic HIV-luciferase infection of MDM. VPX-encoding 
virus-like particles were produced essentially as described 
previously.46 Briefly, 293T cells were transfected using poly-
ethylenimine (Sigma-Aldrich) with the VPX-containing pSIV3+ 
plasmid (provided by A. Cimarelli, Lyon) and the pMD2.G 
(VSV-G envelope) plasmid. The medium was changed after 
16 hours, and supernatants were collected after 48 hours 
and filtered through 0.45 µm low protein binding syringe fil-
ters. MDMs were prepared as follows: monocytes from HIV 
seronegative donors were isolated from total peripheral blood 
after ACK lysis (Lonza, Basel, Switzerland) by CD14 micro-
beads (Miltenyi Biotec, Bergisch Gladbach, Germany). The 
isolated monocytes were matured to produce macrophages 
for 6 days with X-vivo-10 medium (Lonza) supplemented with 
1,000 U/ml granulocyte-macrophage colony-stimulating fac-
tor and 100 ng/ml macrophage colony-stimulating factor. After 
6 days, the medium was changed to X-vivo-10 w/o Cytokines 
for 2 days. VPX-encoding virus-like particles were added onto 
the cells for 2 hours, cells were washed, and then transduced 
overnight with the anti-CCR5 mirGE or control GFP lentivec-
tors. The next day, the cells were washed and kept in culture 
for 4 days prior to infection with R5 tropic NL4-3/luciferase 
virus pseudotyped with ADA envelope virus for 6 hours. After 
6 hours, cells were washed, and new medium added. Cells 
were lysed 24 hours after infection with the Cell Culture lysis 
reagent (Luciferase assay System; Promega, Madison, WI), 
and luciferase was measured with the MLX microplate lumi-
nometer (Dynex Technologies, Chantilly, VA).
Statistical analysis. The statistical analyses were performed 
using GraphPad Prism 5.04 (GraphPad Software, La Jolla, 
CA). We used one-way analysis of variance followed by 
Bonferroni’s multiple comparison test as well as t-test (non 
parametric, Mann–Whitney U-test). In Supplementary Table 
S2, significant difference of incorrect targeting strand pro-
cessing was determined using a proportion test (R prop.test; 
two-sample test for equality of proportions with continuity 
correction). For all tests, P < 0.05 was taken as statistically 
significant.
Algorithm for the design of mirGE-based amplicons for 
 cloning. This algorithm is a compilation of several published 
and on-line references including refs. (47) and (48).
1. Copy your target sequence (ORF, 3′UTR, etc).
2. Use the three following web tools to select at least ten 
target sequences (http://www5.appliedbiosystems.com/ 
tools/siDesign/; http://www.med.nagoya-u.ac.jp/neuro 
genetics/i_Score/i_score.html; http://rna.tbi.univie.ac.at/ 
cgi-bin/RNAxs
3. Select candidates that are in overlapping pools.
4. Blast each 19mer to check that they are targeting no 
other gene other than your target gene.
5. Exclude “bad” candidates by following instructions of 
ref. (48) page 12.
6. Extend 19mer to 22mer by adding nucleotides from 
the original target sequence, either upstream or down-
stream, favoring a resulting complementary sequence 
that will have a T on the 5′ end.47
 This 22mer is the 
basis for the following shRNA design. For human 
CCR5 mRNA (GenBank: NM_000579.3), the result is 
TTTCCATACAGTCAGTATCAAT (22mer).
7. Make a complementary strand to this 22mer, which will 
be the top strand of mirGE context, i.e the targeting 
strand. To be efficiently incorporated into RISC, the 5′ 
terminus A needs to flap, thus make a wobble on the 
complementary strand (Z) 
 5′-ATTGATACTGACTGTATGGAAA 
 3′-ZAACTATGACTGACATACCTTT
8. Make another wobble on the complementary strand 
corresponding to position +12 of the targeting strand, 
to suppress abortive processing.4 As a general rule: 
Antiparallel (targeting) sequence being in blue, 100% 
complementary to target mRNA (in red) 
 5′- NNNNNNNNNNNNNNNNNNNNNN 
 3′- ZNNNNNNNNNNZNNNNNNNNNN
9. Then choose Z to add to bottom oligo according to the N 
in top oligo facing Z. If N is T, make Z a C. If N is C, make 
Z an A. If N is A, make Z a C. If N is G, make Z an A.
10. Replace NNN stretches by sense and antisense oligos 
to make the PCR template oligo
11. Amplify this template with the 5′ and 3′ PCR oligos, as 
described above.
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